Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telemedycyna PolskaWAR:TMP 31 EV-to-EBITDA is -10.57 as of Aug. 24, 2026. GuruFocus rates WAR:TMP with a GF Score™ of 31/100 and a GF Value™ of zł0.80 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 516 Healthcare Providers & Services companies, Telemedycyna Polska ranks worse than 193798.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telemedycyna Polska's enterprise value is zł8.46 Mil.
Telemedycyna Polska's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.80 Mil. Therefore, Telemedycyna Polska's EV-to-EBITDA for today is -10.57.
The historical rank and industry rank for Telemedycyna Polska's EV-to-EBITDA or its related term are showing as below:
WAR:TMP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -381.6 Med: -6.77 Max: 246.62
Current: -10.57
During the past 13 years, the highest EV-to-EBITDA of Telemedycyna Polska was 246.62. The lowest was -381.60. And the median was -6.77.
WAR:TMP's EV-to-EBITDA is ranked worse than 100% of 516
companies
in the Healthcare Providers & Services industry
Industry Median: 10.705
vs WAR:TMP: -10.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Telemedycyna Polska (WAR:TMP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Telemedycyna Polska's PE Ratio (TTM) for today is calculated as:
Telemedycyna Polska's share price for today is zł0.61.
Telemedycyna Polska's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.096.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Telemedycyna Polska's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:TMP vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Telemedycyna Polska's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telemedycyna Polska EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Telemedycyna Polska's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Telemedycyna Polska's EV-to-EBITDA falls into.
Telemedycyna Polska's current Enterprise Value is zł8.46 Mil.
Telemedycyna Polska's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telemedycyna Polska (WAR:TMP) has a EV-to-EBITDA of -10.57 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Telemedycyna Polska. According to the industry distribution chart, Telemedycyna Polska ranks #999999 out of 516 companies in the Healthcare Providers & Services industry.
Is Telemedycyna Polska's EV-to-EBITDA too high?
Telemedycyna Polska's current EV-to-EBITDA is -10.57. Based on the distribution chart, Telemedycyna Polska ranks #999999 out of 516 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Telemedycyna Polska has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telemedycyna Polska's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Telemedycyna Polska ranks #999999 out of 516 companies for EV-to-EBITDA. This places Telemedycyna Polska in the lower half of its industry. The industry median EV-to-EBITDA is 10.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.71, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Telemedycyna Polska. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telemedycyna Polska's current EV-to-EBITDA is -10.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telemedycyna Polska stock overvalued right now?
Based on GuruFocus' analysis, Telemedycyna Polska (WAR:TMP) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.80, compared to a current price of zł0.61 — trading 23.8% below its estimated fair value. The current EV-to-EBITDA is -10.57. Telemedycyna Polska's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Telemedycyna Polska (WAR:TMP), the current EV-to-EBITDA is -10.57 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telemedycyna Polska (WAR:TMP) Overvalued in 2026?
Based on GuruFocus' analysis, Telemedycyna Polska stock appears to be undervalued.
The current stock price of zł0.61 is trading 23.8% below its estimated GF Value™ of zł0.80.
GuruFocus considers Telemedycyna Polska to be Modestly Undervalued.
Key valuation signals for WAR:TMP:
EV-to-EBITDA: -10.57
GF Value™: zł0.80 vs. price of zł0.61 (23.8% below fair value)
No single metric tells the full story. See the WAR:TMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telemedycyna Polska SA offers telecardiology services for individual patients and medical facilities in Poland. The company offers cardiologic care services through telephone and Internet. The company also provides telemedical services to health centres.
31GF Score
Get the complete analysis for WAR:TMP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:TMP has been successfully added to your 
